Should I buy or sell Lipella Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lipella Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LIPO shares. View LIPO analyst ratings or view top-rated stocks .

What is Lipella Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Lipella Pharmaceuticals' stock. Their LIPO share price targets range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 178.6% from the stock's current price. View analysts price targets for LIPO or view top-rated stocks among Wall Street analysts .

How have LIPO shares performed in 2024?

Lipella Pharmaceuticals' stock was trading at $1.02 on January 1st, 2024. Since then, LIPO stock has decreased by 29.6% and is now trading at $0.7180. View the best growth stocks for 2024 here .

Are investors shorting Lipella Pharmaceuticals?

Lipella Pharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 43,700 shares, a drop of 17.7% from the March 15th total of 53,100 shares. Based on an average daily trading volume, of 57,100 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.2% of the shares of the stock are short sold. View Lipella Pharmaceuticals' Short Interest .

When is Lipella Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LIPO earnings forecast .

When did Lipella Pharmaceuticals IPO?

Lipella Pharmaceuticals (LIPO) raised $7 million in an IPO on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75 per share.

How do I buy shares of Lipella Pharmaceuticals?

Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LIPO

Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free LIPO Stock Alerts

$0.72

+0.00 (+0.66%)

(As of 12:37 PM ET)

Compare

Today's Range: $0.72
▼
$0.72
50-Day Range: $0.67
▼
$1.04
52-Week Range: $0.64
▼
$2.71

Volume: 2,305 shs
Average Volume: 52,412 shs
Market Capitalization: $4.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Get Lipella Pharmaceuticals alerts:

Lipella Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 178.6% Upside
$2.00 Price Target
Short Interest: Healthy
1.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.32
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$23,700 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.58 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Lipella Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Lipella Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.24% of the float of Lipella Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lipella Pharmaceuticals has recently decreased by 17.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Lipella Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Lipella Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LIPO.

3.0

News and Social Media Coverage

News Sentiment
Lipella Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Lipella Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for LIPO on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added Lipella Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lipella Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,700.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
39.58% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Lipella Pharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Lipella Pharmaceuticals Stock (NASDAQ:LIPO)

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

LIPO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LIPO Stock News Headlines

March 20, 2024 | insidertrades.com

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Insider Jonathan H. Kaufman Purchases 30,000 Shares

April 17, 2024 | finance.yahoo.com

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

April 19, 2024 | DTI (Ad)

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

April 17, 2024 | globenewswire.com

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

April 15, 2024 | americanbankingnews.com

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Short Interest Update

April 10, 2024 | americanbankingnews.com

Lipella Pharmaceuticals (NASDAQ:LIPO) Now Covered by Analysts at Maxim Group

April 5, 2024 | globenewswire.com

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

April 3, 2024 | markets.businessinsider.com

Lipella Pharmaceuticals Announces Type C Meeting For LP-10 - Quick Facts

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

April 3, 2024 | globenewswire.com

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

March 7, 2024 | finance.yahoo.com

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

March 5, 2024 | markets.businessinsider.com

Lipella Pharma's IND Application For LP-410 Gets FDA's Approval

March 3, 2024 | morningstar.com

Lipella Pharmaceuticals Inc Ordinary Shares LIPO

March 1, 2024 | finance.yahoo.com

Lipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)

February 20, 2024 | finance.yahoo.com

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

February 20, 2024 | globenewswire.com

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

February 9, 2024 | finance.yahoo.com

Lipella Pharmaceuticals Inc. (LIPO)

December 20, 2023 | finanznachrichten.de

Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

December 20, 2023 | finance.yahoo.com

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

December 9, 2023 | morningstar.com

Lipella Pharmaceuticals Inc Ordinary Shares

November 10, 2023 | markets.businessinsider.com

Lipella Pharma: FDA Grants Orphan Designation For LP-310 To Treat Oral Graft-versus-Host Disease

November 10, 2023 | finance.yahoo.com

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

October 25, 2023 | finance.yahoo.com

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

October 24, 2023 | finance.yahoo.com

Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

October 23, 2023 | finance.yahoo.com

Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

October 22, 2023 | msn.com

Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment

October 20, 2023 | benzinga.com

What's Going On With Lipella Pharmaceuticals Stock?

See More Headlines

Receive LIPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipella Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LIPO
CUSIP: N/A
CIK: 1347242
Web: lipella.com
Phone: 412-901-0315
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.00
High Stock Price Target: $2.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +180.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,620,000.00
Net Margins: -1,025.93%
Pretax Margin: -1,026.44%
Return on Equity: -150.13%
Return on Assets: -127.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.91
Quick Ratio: 8.91

Sales & Book Value

Annual Sales: $449,617.00
Price / Sales: 9.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 1.32

Miscellaneous

Outstanding Shares: 6,250,000
Free Float: 3,776,000
Market Cap: $4.46 million
Optionable: Not Optionable
Beta: 1.33

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Jonathan Kaufman M.B.A. (Age 57)
Ph.D., Co-Founder, Chairman, CEO, President, Secretary & Treasurer
Comp: $204.13k
Dr. Michael B. Chancellor M.D. (Age 65)
Co-Founder, Chief Medical Officer & Director
Comp: $195.83k
Mr. Douglas Johnston CPA (Age 39)
Chief Financial Officer
Comp: $185k
Ms. Michele Gruber
Director of Operations
Katie Johnston
Controller

Key Competitors

View All Competitors

Insiders

Jonathan H Kaufman
Bought 30,000 shares on 3/18/2024
Total: $23,700.00 ($0.79/share)

View All Insider Transactions

LIPO Stock Analysis - Frequently Asked Questions

Should I buy or sell Lipella Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lipella Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LIPO shares.
View LIPO analyst ratings or view top-rated stocks.
What is Lipella Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued twelve-month price objectives for Lipella Pharmaceuticals' stock. Their LIPO share price targets range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 178.6% from the stock's current price.
View analysts price targets for LIPO or view top-rated stocks among Wall Street analysts.
How have LIPO shares performed in 2024?: Lipella Pharmaceuticals' stock was trading at $1.02 on January 1st, 2024. Since then, LIPO stock has decreased by 29.6% and is now trading at $0.7180.
View the best growth stocks for 2024 here.
Are investors shorting Lipella Pharmaceuticals?: Lipella Pharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 43,700 shares, a drop of 17.7% from the March 15th total of 53,100 shares. Based on an average daily trading volume, of 57,100 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.2% of the shares of the stock are short sold.
View Lipella Pharmaceuticals' Short Interest.

When is Lipella Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LIPO earnings forecast.
When did Lipella Pharmaceuticals IPO?: Lipella Pharmaceuticals (LIPO) raised $7 million in an IPO on Tuesday, December 20th 2022. The company issued 1,217,391 shares at $5.75 per share.
How do I buy shares of Lipella Pharmaceuticals?: Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIPO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial